European Medicines Agency: AstraZeneca vaccine may have potential link with thrombosis
According to Bloomberg news on April 6, according to the Italian newspaper Il Messaggero, the European Medicines Agency (EMA) believes that AstraZeneca vaccine is potentially linked to blood clots.
Due to concerns about the possible risk of blood clots after vaccination, Denmark, Germany, France, Italy and other countries have announced the suspension of the use of AstraZeneca vaccine in mid-March. Subsequently, the WHO stated on March 17 that given that the vaccine's anti-epidemic effect is greater than the potential risk, it is still recommended to continue vaccination.
The European Medicines Agency issued preliminary findings on March 18, stating that the AstraZeneca vaccine "benefits outweigh the risks," but it does not rule out that it is related to a very small number of thrombosis cases. Subsequently, France, Germany and many other countries resumed vaccination of this vaccine one after another.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-09
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
AZD1222 Oxford Phase III trials interim analysis results published in The Lancet
-
AstraZeneca: New covid-19 vaccine expected in January next year
-
These thrombus prolongs in the heart and falls off, causing cerebral infarction.
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
Novo Nordisk Submits Higher Dose of Wegovy One in Three Achieves Over 25 Percent Weight Loss
-
Eisai Pharma Unveils Bold Plan: $100 Million Global Center Set to Transform Visakhapatnam Now
Recommend Reading
-
Over 70% of Patients Find Relief in Bayer’s New Breakthrough Drug for Breast Cancer Menopause Symptoms
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
FDA Fast-Tracks U.S. Drug Manufacturing
-
DIC to Build New Epoxy Resin Production Facility at Chiba Plant
-
ECHEMI High Quality Inquiries (4-8 Aug)
-
Sika Impacted by Weaker Dollar in H1, Lowers Full-Year Sales Guidance
-
This week, China's 180CST fuel oil market consolidates at high levels
-
BASF's Zhanjiang Plant Steam Cracking Unit Commences Operation